A share price of Phathom Pharmaceuticals Inc [PHAT] is currently trading at $16.47, up 5.17%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PHAT shares have gain 4.57% over the last week, with a monthly amount drifted -10.92%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on May 03, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $24. Previously, Needham reaffirmed its Buy rating on January 05, 2024, and elevated its price target to $26. On August 09, 2023, H.C. Wainwright initiated with a Buy rating and assigned a price target of $28 on the stock. Evercore ISI upgraded its rating to a Outperform. Craig Hallum initiated its recommendation with a Buy and recommended $21 as its price target on March 13, 2023. Jefferies started tracking with a Buy rating for this stock on October 21, 2022, and assigned it a price target of $16. In a note dated May 06, 2022, Evercore ISI downgraded an In-line rating on this stock.
Phathom Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $6.07 and $19.71. Currently, Wall Street analysts expect the stock to reach $25.83 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $16.47 at the most recent close of the market. An investor can expect a potential return of 56.83% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -25.49%, Pretax Profit Margin comes in at -29.96%, and Net Profit Margin reading is -29.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.93, Equity is 2.51 and Total Capital is -0.93. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.90 points at the first support level, and at 15.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.98, and for the 2nd resistance point, it is at 17.49.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Phathom Pharmaceuticals Inc [NASDAQ:PHAT] is 6.48. Also, the Quick Ratio is 6.44, while the Cash Ratio stands at 5.88. Considering the valuation of this stock, the price to sales ratio is 113.38.
Transactions by insiders
Recent insider trading involved Nabulsi Azmi, Chief Operating Officer, that happened on Jul 15 ’24 when 10901.0 shares were sold. CFO and CBO, Henderson Molly completed a deal on Jul 15 ’24 to sell 4325.0 shares. Meanwhile, President and Chief Executive Curran Terrie sold 33848.0 shares on Jul 15 ’24.
